Recently, the FDA granted breakthrough device designation to Roche for its Elecsys
Neurofilament Light Chain (NfL) test as a potential tool for the detection of disease activity in …

EP: 2. Updates on NfL Levels in MS Clinical Trials Now Viewing EP: 3. Implementing NfL in
MS in Clinical Practice EP: 4. Access to Biomarkers in MS Bruce Hughes, MD: Regarding …

LOS ANGELES—Evidence is growing that neurofilament light chain (NfL) protein in the
blood could give crucial insights into the disease status in multiple sclerosis patients, along …

Markedly Reduced by Natalizumab” Ann Neurol 2011; 69: 83-89 For the past decade both
biomarker research and treatment strategies in multiple sclerosis were focused on …

EP: 1. Use of Neurofilament Light Chain (NfL) as a Biomarker in Multiple Sclerosis (MS) EP:
2. Updates on NfL Levels in MS Clinical Trials EP: 3. Implementing NfL in MS in Clinical …

Objective: To validate a neurofilament light chain (NfL) assay on a clinical autoanalyzer to
enable clinical utility for a broad range of neurogenerative diseases and conditions …

Multiple sclerosis (MS) is an inflammatory disease of the CNS resulting in neurologic
disability that often progresses over time. Because the prognosis varies highly among …

Objective: To present correlations between neurofilament light chain (NfL) levels in
cerebrospinal fluid (CSF), serum or plasma, with MRI disease activity, in predominantly …

Objective: To investigate the ability of serum NfL levels to identify brain MRI activity.
Background: Neurofilament light chain (NfL) serum level is associated with disease activity …

In addition to the mysteries and autobiographies that some of you may be packing for a late
summer vacation or long weekend, consider including the current issue of N2. Each article …